[Treatment of refractory malignant lymphomas with cisplatin, vinblastine, and bleomycin].
Eighteen patients with advanced malignant lymphoma resistant to previous chemotherapy were treated with combination chemotherapy consisting of cisplatinum, vinblastine and bleomycin. Ten patients (55%) responded (two complete remissions and eight partial). The median survivaL time of patients responding was 15 weeks which was better that the one in patients with no response (3 weeks). Toxicity was mild. We believe that the use of cisplatinum could be useful in patients with refractory malignant lymphoma in combination with other drugs.
Avilés
A
A
Departamento de Hematología, Hospital de Oncología, Centro Médico Nacional, I.M.S.S., México, D.F.
Díaz-Maqueo
J C
JC
Torras
V
V
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D004341:Drug Evaluation; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D009364:Neoplasm Recurrence, Local; D012074:Remission Induction; D014747:Vinblastine / Q000008:administration & dosage
D001761:Bleomycin; D014747:Vinblastine; D002945:Cisplatin
Tratamiento de linfomas malignos refractarios con cisplatino vinblastina y bleomicina.